Actively Recruiting
Assessment of Pro-Resolution Mediator Levels in Stage III and IV Periodontitis Before and After Non-Surgical Periodontal Therapy
Led by Cairo University · Updated on 2025-01-23
22
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating pro-resolution mediator levels during non-surgical periodontal therapy in adults with Stage III and IV periodontitis compared to healthy individuals. Periodontitis is a chronic inflammatory disease that causes slow destruction of the tissues supporting teeth, potentially leading to tooth loss and systemic issues. The study aims to better understand the role of lipid mediators that help resolve inflammation and promote tissue healing in this condition. The treatment involves professional mechanical plaque control, which includes motivating patients to improve oral hygiene, removing plaque and calculus professionally, adjusting faulty dental restorations, and teaching brushing and interdental cleaning techniques. This approach is applied before and after treatment to observe changes in mediator levels. The study design compares patients with periodontitis before and after therapy to a group of healthy patients. Participants will undergo assessments of pro-resolution mediator levels at several time points: before treatment, one day, one month, and three months after therapy. Researchers will measure changes in lipoxin A4 levels in gingival crevicular fluid. The study also includes clinical evaluations such as probing depths and bleeding sites. The total participation duration includes these follow-up periods to monitor inflammation resolution and treatment effects.
CONDITIONS
Official Title
Assessment of Pro-Resolution Mediator Levels in Periodontitis Stage III and IV Before and After Periodontal Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients above 18 years old
- Interdental clinical attachment loss at site of greatest loss 5 mm or extending to middle third of the root
- Interdental clinical attachment loss at site of greatest loss 8 mm or extending to apical third of the root
- Probing depth 6 mm
- Vertical bone loss 3 mm
- Tooth loss due to periodontitis of 4 teeth for Stage III
- Tooth loss due to periodontitis of 5 teeth for Stage IV
- Furcation involvement Class II or III, moderate ridge defect
- Systemically healthy patients (healthy group)
- Patients aged between 16 and 80 years (healthy group)
- Patients with at least 20 teeth (healthy group)
- Less than 10% bleeding sites with probing depths 3 mm (healthy group)
- Absence of erythema and oedema (healthy group)
You will not qualify if you...
- Pregnancy or lactation
- Smoking more than 20 cigarettes daily
- Immuno-inflammatory conditions of the skin and oral mucosa
- Systemic conditions affecting bone turnover and periodontal health (e.g., endocrine and connective tissue diseases, bisphosphonate therapy, gastrointestinal diseases related to nutrition and mineral metabolism)
- Periodontal or orthodontic treatment within 6 months before study start
- Use of anti-inflammatory and antimicrobial agents within 3 months before sampling
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Faculty of Dentistry-Cairo University
Manial, Cairo Governorate, Egypt, 12311
Actively Recruiting
2
faculty of dentistry Cairo university
Cairo, Egypt
Actively Recruiting
Research Team
H
Husam Ghazi Alharbi, Master Degree
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here